COVIRIX Medical, incorporated in March 2020, is repurposing pharmaceutical drugs with proven antiviral efficacy against SARS-CoV-2 and adjunctive anti-inflammatory properties for delivery via oral and intranasal inhalation as targeted COVID-19 treatment options. The company's business plan includes concomitant development of an inhaled antiviral and a non-steroidal anti-inflammatory intended to combat Long-COVID syndrome, with potential to replace inhaled steroids for inflammatory pulmonary conditions including asthma, COPD and ILD. The team has over 200 years of combined industry experience in healthcare, biotech, drug development, synthesis, testing and investment banking. COVIRIX is seeking active collaborative engagement with health authorities and industry partners to expedite delivery of its antiviral solutions.
